Company Gubra A/S

Equities

GUBRA

DK0062266474

Biotechnology & Medical Research

Business Summary

Sales per Business

Sales per region

Managers

Members of the board

Share class

Shareholders

Holdings

Company contact information

Sector

Sales per Business

Sales per region

Sector Bio Therapeutic Drugs

Market Closed - Nasdaq Copenhagen Other stock markets 10:59:35 2024-05-08 am EDT			5-day change	1st Jan Change
338 ^DKK	-2.87%		+14.19%	+170.40%

Apr. 17	Gubra Unveils UCN2 as Novel Anti-Obesity Drug Candidate for Healthy Weight Loss	CI
Mar. 29	Certain Shares of Gubra A/S are subject to a Lock-Up Agreement Ending on 29-MAR-2024.	CI

Gubra A/S is a Denmark-based biotechnology company specialized in high-end pre-clinical contract research and peptide-based drug discovery within metabolic and fibrotic diseases. The Companyâs operations are anchored around its advanced technology platforms and utilization of automation, robotization and digitalization, including machine learning (ML) and artificial intelligence (AI). The Company's business activity are divided into two segments: The CRO Segment offers specialized profitable pre-clinical contract research services at attractive margins within metabolic and fibrotic disease areas such as diabetes, obesity, chronic kidney disease; and The Discovery and Partnership Segment is based on an internal target and drug discovery engine for identification and design of peptide-based drug partnering candidates within metabolic and fibrotic diseases.

Number of employees: 220

DKK in Million	2022	Weight	2023	Weight	Delta
Pre-Clinical Contract Research 82.2 %	131	65.5 %	169	82.2 %	+29.04%
Discovery and Partnership 17.8 %	69	34.5 %	36	17.8 %	-46.99%

DKK in Million	2022	Weight	2023	Weight	Delta
United States 42.0 %	67	33.6 %	86	42.0 %	+28.36%
Germany 21.5 %	77	38.6 %	44	21.5 %	-42.86%
Denmark 16.1 %	15	7.5 %	33	16.1 %	+120.00%
Europe 15.3 %	30	15.1 %	31	15.3 %	+3.80%
Other 3.9 %	4	2.2 %	8	3.9 %	+84.04%
North America 1.4 %	6	3.0 %	3	1.4 %	-53.10%

Managers	Title	Age	Since
Niels Vrang FOU	Founder	56	07-12-31
Henrik Blou CEO	Chief Executive Officer	45	16-05-31
Kristian Borbos DFI	Director of Finance/CFO	46	22-07-31
Helle Kirstein Erichsen COO	Chief Operating Officer	-	17-03-31
Kristoffer Rigbolt CTO	Chief Tech/Sci/R&D Officer	-	22-04-30
Mads Buhl Axelsen CTO	Chief Tech/Sci/R&D Officer	66	22-07-31
Trine Nygaard Hamann PRN	Corporate Officer/Principal	-	20-02-29

Members of the board	Title	Age	Since
Arndt Justus Georg Schottelius BRD	Director/Board Member	58	21-12-31
Alexander Thomas Martensen-Larsen BRD	Director/Board Member	48	21-12-31
Jacob Jelsing FOU	Founder	50	07-12-31
Henriette Draebye Rosenquist BRD	Director/Board Member	55	21-12-31

	Vote	Quantity	Free-Float	Company-owned shares	Total Float
Stock A	1	16,349,703	5,000,292 ( 30.58 %)	59,271 ( 0.3625 %)	30.58 %

Name	Equities	%	Valuation
Jacob Jelsing 31.72 %	5,186,030	31.72 %	219 M kr
Niels Vrang 31.72 %	5,186,030	31.72 %	219 M kr
Danske Bank A/S (Investment Management) 4.348 %	710,825	4.348 %	30 M kr
Henrik Blou 3.098 %	506,499	3.098 %	21 M kr
GUBRA A/S 0.3625 %	59,271	0.3625 %	3 M kr
Schroder Investment Management (Europe) SA (Finland) 0.3058 %	50,000	0.3058 %	2 M kr
Cicero Fonder AB 0.1223 %	20,000	0.1223 %	844 310 kr
Sydbank A/S (Investment Management) 0.0119 %	1,939	0.0119 %	81 856 kr

Name	Equities	%	Valuation
GUBRA A/S 0.36%	59,271	0.36%	2,502,156 $

Gubra A/S

Hørsholm Kongevej 11B

2970, Hørsholm

+45 31 52 26 50

http://www.gubra.dk

Healthcare

Pharmaceuticals & Medical Research

Biotechnology & Medical Research

Biotechnology & Medical Research

Bio Therapeutic Drugs

	1st Jan change	Capi.
GUBRA A/S	+170.40%	795M
VERTEX PHARMACEUTICALS INCORPORATED	+3.91%	109B
REGENERON PHARMACEUTICALS, INC.	+10.87%	105B
ARGENX SE	+1.28%	22.25B
BIONTECH SE	-13.14%	22.09B
GENMAB A/S	-7.05%	18.68B
WUXI APPTEC CO., LTD.	-38.36%	17.58B
BEIGENE, LTD.	-10.66%	16.85B
NEUROCRINE BIOSCIENCES, INC.	+3.75%	13.76B
SAREPTA THERAPEUTICS, INC.	+36.70%	12.46B

Bio Therapeutic Drugs